<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375491</url>
  </required_header>
  <id_info>
    <org_study_id>090395</org_study_id>
    <secondary_id>5M01RR000827</secondary_id>
    <secondary_id>P30DK063491</secondary_id>
    <nct_id>NCT01375491</nct_id>
  </id_info>
  <brief_title>Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans</brief_title>
  <acronym>DOXY</acronym>
  <official_title>Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruth L. Kirschstein National Research Service Award</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a heightened state of inflammation in which production of cytokines and matrix
      metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin
      resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance
      insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes
      (DM2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical
      trial conducted in an academic tertiary care center.

      Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).

      Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also
      evaluated at D84 after DOX 100mg twice daily or PL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMP Activity</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMP Activity</measure>
    <time_frame>Day 84</time_frame>
    <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Measure of global inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 84</time_frame>
    <description>Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with DM2 receiving doxycycline 100mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pills prepared identical to doxycycline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>generic doxycycline 100mg twice daily</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator to doxycycline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, medically stable, able to give informed consent, and comply with the
             protocol.

          -  Obesity with BMI &gt;30 kg/m2.

          -  DM2 for less than 10 years.

          -  7.5% &lt; HA1C &lt; 10%

          -  Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)

        Exclusion Criteria:

          -  Mental states that would preclude complete understanding of the protocol and
             compliance.

          -  Chronic illness such as renal failure (with creatinine clearance &lt;80 ml/min for
             Specific Aim 2).

          -  Women of child-bearing age because of the potential hazard to the fetus (doxycycline
             may cause permanent discoloration of the teeth and deposition in bone inhibiting
             growth) and because doxycycline may render oral contraceptives less effective.

          -  Nursing mothers.

          -  Allergy to tetracyclines.

          -  Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant
             therapy, antacids containing aluminum, calcium, or magnesium, iron-containing
             preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or
             methoxyflurane, thiazolidinediones (TZD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Herbst, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Clinical trials Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeLano FA, Schmid-Schönbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008 Aug;52(2):415-23. doi: 10.1161/HYPERTENSIONAHA.107.104356. Epub 2008 Jul 7.</citation>
    <PMID>18606910</PMID>
  </reference>
  <results_reference>
    <citation>Frankwich K, Tibble C, Torres-Gonzalez M, Bonner M, Lefkowitz R, Tyndall M, Schmid-Schönbein GW, Villarreal F, Heller M, Herbst K. Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond). 2012 Oct 1;9(1):35. doi: 10.1186/1476-9255-9-35.</citation>
    <PMID>23025537</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>December 5, 2019</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>doxycycline</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>obesity</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study included non-type 2 diabetics controls (n = 15), and type two diabetics subjects randomized to placebo (n = 13) or doxycycline 100 mg twice daily (n = 11).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxycycline</title>
          <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>non- type two diabetics to serve as a control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxycycline</title>
          <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Participants enrolled without type 2 diabetes to serve as a control</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.3" spread="1.9"/>
                    <measurement group_id="B2" value="54.5" spread="1.7"/>
                    <measurement group_id="B3" value="48.7" spread="3.1"/>
                    <measurement group_id="B4" value="54.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MMP Activity</title>
        <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.</description>
        <time_frame>Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
          </group>
          <group group_id="O3">
            <title>Control Arm</title>
            <description>The study included non-DM2 controls (n = 15), but the non DM2 controls were not evaluated on day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>MMP Activity</title>
          <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.</description>
          <units>uM 5-FAM/h-ug protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="13.3"/>
                    <measurement group_id="O2" value="43.8" spread="4"/>
                    <measurement group_id="O3" value="47.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP</title>
        <description>Measure of global inflammation.</description>
        <time_frame>Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
          </group>
          <group group_id="O3">
            <title>Control Arm</title>
            <description>The study included non-DM2 controls (n = 15), but the non DM2 controls were not evaluated on day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>CRP</title>
          <description>Measure of global inflammation.</description>
          <units>microgram/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="3.3"/>
                    <measurement group_id="O2" value="5.9" spread="1.8"/>
                    <measurement group_id="O3" value="1.9" spread=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>See published paper.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>See published paper.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>See published paper.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MMP Activity</title>
        <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
        <time_frame>Day 84</time_frame>
        <population>Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
          </group>
        </group_list>
        <measure>
          <title>MMP Activity</title>
          <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
          <population>Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</population>
          <units>uM 5-FAM/h-ug protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" spread="4.3"/>
                    <measurement group_id="O2" value="56.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP</title>
        <description>Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
        <time_frame>Day 84</time_frame>
        <population>Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
          </group>
        </group_list>
        <measure>
          <title>CRP</title>
          <description>Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</description>
          <population>Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.</population>
          <units>microgram/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.4"/>
                    <measurement group_id="O2" value="6.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This information is being entered from a publication, since the Principal Investigator is no longer associated with the institution. The publication does not report on adverse events and so there is no way to report these numbers.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxycycline</title>
          <description>Participants with DM2 receiving doxycycline 100mg BID
Doxycycline : generic doxycycline 100mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Pills prepared identical to doxycycline.
Placebo : Placebo comparator to doxycycline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This information is being entered from a publication, since the Principal Investigator is no longer associated with the institution. The publication does not report on adverse events and so there is no way to report these numbers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Karen Louise Herbst</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>858-552-8585 ext 7384</phone>
      <email>kaherbst@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

